Stammdaten
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Unternehmen & Branche
| Name | Precipio, Inc. |
|---|---|
| Ticker | PRPO |
| CIK | 0001043961 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Diagnostics & Research |
| SIC | 3826 · Laboratory Analytical Instruments |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 56,2 Mio. USD |
| Beta | 1,20 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 24,049,000 | -363,000 | -0.23 | 21,317,000 | |
| 2025-09-30 | 10-Q | 6,767,000 | -0.05 | 21,153,000 | ||
| 2025-06-30 | 10-Q | 5,654,000 | 0.05 | 18,816,000 | ||
| 2025-03-31 | 10-Q | 4,929,000 | -0.59 | 17,785,000 | ||
| 2024-12-31 | 10-K | 18,532,000 | -4,290,000 | -2.93 | 16,996,000 | |
| 2024-09-30 | 10-Q | 5,209,000 | -0.42 | 16,951,000 | ||
| 2024-06-30 | 10-Q | 4,441,000 | -0.83 | 17,318,000 | ||
| 2024-03-31 | 10-Q | 3,432,000 | -1.46 | 16,624,000 | ||
| 2023-12-31 | 10-K | 15,197,000 | -4.51 | 18,101,000 | 14,429,000 | |
| 2023-09-30 | 10-Q | 4,518,000 | -1.04 | 19,053,000 | 12,937,000 | |
| 2023-06-30 | 10-Q | 3,533,000 | -1.88 | 19,472,000 | 14,026,000 | |
| 2023-03-31 | 10-Q | 2,817,000 | -2.61 | 19,423,000 | 14,160,000 | |
| 2022-12-31 | 10-K | 9,412,000 | -10.73 | 21,504,000 | 16,302,000 | |
| 2022-09-30 | 10-Q | 2,215,000 | -2.79 | 23,547,000 | 18,196,000 | |
| 2022-06-30 | 10-Q | 2,359,000 | -0.09 | 25,979,000 | 20,513,000 | |
| 2022-03-31 | 10-Q | 2,447,000 | -0.20 | 27,971,000 | 22,206,000 | |
| 2021-12-31 | 10-K | 8,849,000 | -0.40 | 30,439,000 | 24,564,000 | |
| 2021-09-30 | 10-Q | 2,246,000 | -0.08 | 31,605,000 | 25,880,000 | |
| 2021-06-30 | 10-Q | 2,344,000 | -0.14 | 33,540,000 | 27,227,000 | |
| 2021-03-31 | 10-Q | 1,824,000 | -0.08 | 20,423,000 | 14,530,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Sabet Ahmed Zaki | Officer, Chief Operating Officer | Open Market Purchase | 19 | 27.93 | 530.67 | +3,3% | |
| 2026-01-02 | Sabet Ahmed Zaki | Officer, Chief Operating Officer | Open Market Purchase | 20 | 23.40 | 468.00 | +3,0% | |
| 2026-01-02 | Sabet Ahmed Zaki | Officer, Chief Operating Officer | Open Market Purchase | 20 | 23.40 | 468.00 | +3,0% | |
| 2025-10-01 | Sabet Ahmed Zaki | Officer, Chief Operating Officer | Open Market Purchase | 25 | 19.50 | 487.50 | +3,1% | |
| 2025-10-01 | Sabet Ahmed Zaki | Officer, Chief Operating Officer | Open Market Purchase | 25 | 19.50 | 487.50 | +3,1% | |
| 2025-09-08 | LAPORTE KATHLEEN | Director | Open Market Sale | -6,152 | 20.06 | -123,409.12 | -778,2% | |
| 2025-07-08 | Sabet Ahmed Zaki | Officer, Chief Operating Officer | Open Market Purchase | 31 | 16.30 | 505.30 | +3,2% | |
| 2025-07-08 | Sabet Ahmed Zaki | Officer, Chief Operating Officer | Open Market Purchase | 31 | 16.30 | 505.30 | +3,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.